Skip to content

Safety testing of cosmetic products using Patch Test

Evaluation of Dermatological safety of Investigational products by primary irritation patch test on healthy human volunteers of varied skin types

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021243
Enrollment
24
Registered
2019-09-13
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Product 1 to Product 7 Rinse off Product 8 to Product 10 Skin Leave - on: For all 10 leave on product, it is placed directly in the aluminum chambers of the patch and applied on the bac

Sponsors

ITC Life Sciences Technology Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy male and female subjects in the age group of 18-55 years(both age inclusive) 2. Subjects with Fitzpatrick skin type III to V 3. Subjects willing to give a voluntary written informed consent 4. Subjects willing to maintain the test patches in designated positions for 24 Hours 5. Subjects having not participated in a similar investigation in the past two weeks 6. Subjects willing to come for regular follow up visits 7. Subjects ready to follow instructions during the study period 8. Subjects without any open wounds, cuts, abrasions, irritation symptoms

Exclusion criteria

Exclusion criteria: 1. Subjects with Infection/ allergy/ irritation symptoms on the upper back area identified for patch application 2. Subjects with any kind of skin allergy, antecedents or atopy or cutaneous disease which may influence the study results 3. Subject is Pregnant or Lactating 4. Athletes and subjects with history of excessive sweating 5. Subjects on oral corticosteroid, or using any topical or systemic medicine which might interfere with the study results 6. Subjects participating in any other cosmetic or therapeutic trial 7. Subjects with any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness

Design outcomes

Primary

MeasureTime frame
Safety assessment of investigational products for irritation potential using Draize scale at 0 hour(30 minutes post patch removal, 24hrs and 7days post patch removalTimepoint: Safety assessment of investigational products for irritation potential using Draize scale at 0 hour(30 minutes post patch removal), 24hrs and 7days (post patch removal)

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactRajat Gupta

CIDP Biotech India Pvt Ltd

a.jain@cidp-cro.com09582645711

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026